GraftWorx (Alio) launches evaluation of remote monitoring solution for dialysis patients

[vc_row row_height_percent=”0″ override_padding=”yes” h_padding=”2″ top_padding=”4″ bottom_padding=”2″ overlay_alpha=”100″ gutter_size=”3″ column_width_percent=”100″ shift_y=”0″ z_index=”0″ row_height_use_pixel=””][vc_column column_width_percent=”80″ gutter_size=”3″ style=”light” overlay_alpha=”50″ shift_x=”0″ shift_y=”0″ shift_y_down=”0″ z_index=”0″ medium_width=”0″ mobile_width=”0″ zoom_width=”0″ zoom_height=”0″][vc_column_text]GraftWorx (Alio) has commenced a service evaluation in collaboration with the Academic Health Science Network (AHSN) and a National Health Service (NHS) Hospital Foundation Trust based in the North East of England.

After evaluating early data against standard measures, the teams hope to undertake formal studies that will utilise the Graftworx (Alio) remote monitoring solution to assess patients on dialysis and those with heart failure. Cumulatively, these studies will gather both clinical and outcome data on 150 patients for up to three years, over the course of their existing treatment in-clinic as well as outside the clinic.[/vc_column_text][/vc_column][/vc_row]